BioSpace News Archive

DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of

Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System Next-generation technology provides easy, effective clot removal from peripheral arterial vasculature EDEN PRAIRIE, Minn.--( BUSINESS WIRE )-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Poun

The National Comprehensive Cancer Network® (NCCN®) today announced the publication of the organization’s first patient and caregiver resource focused on a childhood cancer type

Rediscovery Life Sciences, LLC (RLS), a clinical-stage biotechnology company, announced the closing of its most recent financing. The Series B financing was co-led by REX Health Ventures (the investment arm of UNC REX Healthcare) and Orlando Health Ventures. RLS will use the proceeds to fund a Phase 2 trial of suramin in diure

Yulong Eco-Materials Limited / EV Biologics, Inc. (OTC PINK:YECO) today announced that it intends to list its Securitized Token Offering “STO” on the CryptoSX digital exchange.

Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) has entered into a definitive share exchange agreement, dated effective September 22, 2020 (the “Share Exchange Agreement”), with 1265292 B.C. Ltd., doing business as Cannafeels (“Cannafeels”), and the shareholders of Cannafeels (the “Shareholders”),

Cognoa’s autism diagnostic device is positioned to be the first FDA-cleared digital solution enabling pediatricians to diagnose autism - a paradigm shift in the standard of care

The study, now published in the JMIR academic journal, examines the predictive accuracy of Diabits and the correlation between daily use of the app and blood glucose control

Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce it has raised A$27,950,000 (before costs) in a placement to institutional, professional and sophisticated investors that will result in 21,500,000 full paid ordinary shares being issued at A$1.30 per share (Placement).

A new study in the Annals of Surgical Oncology demonstrates that Kubtec Medical Imaging’s Mozart® 3D specimen tomosynthesis technology reduces the need for re-excision following breast cancer surgery by more than 50% when compared with 2D-image guided radiographs.